Acceleron Pharma Equity 2025

Acceleron Pharma Aktienanalyse

What does Acceleron Pharma do?

Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Acceleron Pharma's Equity

Acceleron Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Acceleron Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Acceleron Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Acceleron Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Acceleron Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Acceleron Pharma stock

What is the equity of Acceleron Pharma this year?

Acceleron Pharma has equity of 0 USD this year.

What was the equity of Acceleron Pharma compared to the previous year?

The equity of Acceleron Pharma has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Acceleron Pharma?

A high equity is advantageous for investors of Acceleron Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Acceleron Pharma?

A low equity can be a risk for investors of Acceleron Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Acceleron Pharma affect the company?

An increase in equity of Acceleron Pharma can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Acceleron Pharma affect the company?

A reduction in equity of Acceleron Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Acceleron Pharma?

Some factors that can affect the equity of Acceleron Pharma include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Acceleron Pharma so important for investors?

The equity of Acceleron Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Acceleron Pharma take to change the equity?

To change equity, Acceleron Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Acceleron Pharma pay?

Over the past 12 months, Acceleron Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acceleron Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Acceleron Pharma?

The current dividend yield of Acceleron Pharma is .

When does Acceleron Pharma pay dividends?

Acceleron Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acceleron Pharma?

Acceleron Pharma paid dividends every year for the past 0 years.

What is the dividend of Acceleron Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acceleron Pharma located?

Acceleron Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acceleron Pharma from 10/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2025.

When did Acceleron Pharma pay the last dividend?

The last dividend was paid out on 10/20/2025.

What was the dividend of Acceleron Pharma in the year 2024?

In the year 2024, Acceleron Pharma distributed 0 USD as dividends.

In which currency does Acceleron Pharma pay out the dividend?

The dividends of Acceleron Pharma are distributed in USD.